[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637246":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":35,"locations":25,"responsibleParty":41,"collaborators":25,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":25,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":25,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":66,"whyStopped":25,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":25},{"fullName":5,"class":6},"Yuhan Corporation","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"A(RTRT)","EXPERIMENTAL","22 subjects, Cross-over, Single dose YHR2603 on period 1 and 3, Single dose of YHP2508C on period 2 and 4.",[13,14],"Drug: YHP2508C","Drug: YHR2603",{"label":16,"type":10,"description":17,"interventionNames":18},"B(TRTR)","22 subjects, Cross-over, Single dose YHP2508C on period 1 and 3, Single dose of YHR2603 on period 2 and 4.",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","YHP2508C","Test drug",[9,16],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"YHR2603","Comparator drug",[9,16],[31],{"name":32,"affiliation":33,"role":34},"GIMPO WOORI HOSPITAL","11, Gamam-ro, Gimpo-si, Gyeonggi-do, Republic of Korea","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":25,"email":40},"Jungwook Lee, MS","CONTACT","82-2-828-0504","clinicaltrials@yuhan.co.kr",{"type":42,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100637246","phase-1-bioequivalence-study-between-yhp2508c-and-yhr2603-in-healthy-subjects-100637246",false,"NCT07584304","Bioequivalence Study Between YHP2508C and YHR2603 in Healthy Subjects","An Open-label, Randomized, Fasting, Single-dose, Oral Administration, 2-sequence, 4-period, Replicate Crossover Study to Evaluate Bioequivalence Between YHP2508C and YHR2603 in Healthy Subjects","Inclusion Criteria:\n\n* BMI 18-30 kg\u002Fm2\n* Those without clinically significant congenital or chronic diseases\n\nExclusion Criteria:\n\n* Those who have participated in a bioequivalence study or other clinical trials and have been administered investigational products within 6 months prior to the first administration.\n* Those who are judged ineligible to participate in the trial by the principal investigator.\n* Female volunteers who are pregnant, suspected to be pregnant or breastfeeding.",true,"ALL","19 Years","54 Years",{"count":55,"type":56},44,"ESTIMATED","INTERVENTIONAL",[59],"PHASE1","An open-label, randomized, fasting, single-dose, oral administration, 2-sequence, 4-period, replicate crossover study to evaluate bioequivalence between YHP2508C and YHR2603 in healthy subjects",[62],"Healthy Subjects",[64,65],"Pharmacokinetics","Bioequivalence","NOT_YET_RECRUITING","2026-05-12",{"date":69,"type":70},"2026-05-13","ACTUAL",{"date":72,"type":56},"2026-07-10",{"date":74,"type":56},"2026-09-15",{"name":5,"class":6}]